FiercePharma

GSK's Advair ® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
FiercePharma

NEJM publishes results of GSK's long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM).
Healio

FDA approves first generic Advair Diskus for asthma, COPD

Please provide your email address to receive an email when new articles are posted on . The FDA recently issued approval to the first generic version of ...
KTVU

Asthma inhaler to be discontinued in January – here's what patients should know

A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...
Medscape

Fluticasone Propionate via Diskus[TM] Inhaler at Half the Microgram Dose of Budesonide via Turbuhaler[TM] Inhaler

Objective: To evaluate the efficacy and tolerability of two inhaled corticosteroid treatment regimens, fluticasone propionate (FP) delivered from a Diskus TM inhaler and budesonide delivered from a ...